Takeda-Lundbeck Antidepressant Shows Promise In Final U.S. Trial
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's Brintellix (vortioxetine) antidepressant, which it is developing in the U.S. with Denmark's H. Lundbeck, has shown in a Phase III trial to be successful in improving symptoms.